Organogenesis Holdings Inc. provided earnings guidance for the fiscal year ending December 31, 2022. For the year, the company expects net revenue of between $465 million and $490 million, representing a decrease of approximately 1% to an increase of 5% year-over-year, and 2% to 7% on an adjusted basis, as compared to net revenue of $467.4 million for the year ended December 31, 2021. Net income in a range of approximately $26 million to $36 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.65 USD | +6.00% | +3.11% | -35.21% |
05-13 | Morgan Stanley Lowers Price Target on Organogenesis Holdings to $3 From $3.50, Keeps Equalweight Rating | MT |
05-10 | Health Care Edges Higher Amid Rotation to Utilities - Health Care Roundup | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.21% | 351M | |
+55.70% | 59.34B | |
+42.95% | 40.24B | |
-5.39% | 39.88B | |
-5.56% | 28.55B | |
+16.46% | 27.26B | |
-20.56% | 19.23B | |
+33.03% | 12.61B | |
+25.85% | 12.28B | |
+2.72% | 12.49B |
- Stock Market
- Equities
- ORGO Stock
- News Organogenesis Holdings Inc.
- Organogenesis Holdings Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022